欧洲共识建议:儿童IgA血管炎的诊断与治疗——SHARE倡议
SHARE倡议依据EULAR标准操作流程,通过系统文献综述和16位国际专家名义小组共识,制定了儿童IgA血管炎(IgAV)的诊断与治疗推荐。共接受7条诊断推荐和19条治疗推荐,涵盖皮肤与肾脏活检、肾脏检查、影像学、镇痛、ACEI使用、糖皮质激素非肾脏适应症及IgAV肾炎的分层治疗。
要点
- 共形成7条诊断推荐和19条治疗推荐,推荐以≥80%专家同意为接受标准。
- 诊断推荐涉及皮肤和肾脏活检的合理使用、肾脏检查及影像学。
- 治疗推荐强调适当镇痛、ACEI使用及按轻中重度IgAV肾炎分层用药。
核心结论
- SHARE倡议提供了儿童IgAV诊断与治疗的国际循证推荐,有助于改善和统一诊疗。
研究设计与样本
- 依据EULAR标准操作流程,经系统文献综述和16位国际专家在线调查及共识会议(名义小组技术)制定,推荐接受阈值为≥80%专家同意。
主要发现
- 共接受7条诊断推荐和19条治疗推荐。
- 诊断推荐包括皮肤和肾脏活检的适当使用、肾脏检查及影像学。
- 治疗推荐包括适当镇痛、ACEI使用、糖皮质激素非肾脏适应症,以及轻中重度IgAV肾炎的分层治疗和维持治疗。
关键数值与推荐
- 推荐接受标准为≥80%专家同意。
临床怎么用
- 临床可参照该推荐规范儿童IgAV的诊断检查(皮肤/肾脏活检、肾脏评估、影像学)及分层治疗(镇痛、ACEI、糖皮质激素及二线药物)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: IgA vasculitis (IgAV, formerly known as Henoch-Schönlein purpura) is the most common cause of systemic vasculitis in childhood. To date, there are no internationally agreed, evidence-based guidelines concerning the appropriate diagnosis and treatment of IgAV in children. Accordingly, treatment regimens differ widely. The European initiative SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) aims to optimize care for children with rheumatic diseases. The aim therefore was to provide internationally agreed consensus recommendations for diagnosis and treatment for children with IgAV. METHODS: Recommendations were developed by a consensus process in accordance with the EULAR standard operating procedures. An extensive systematic literature review was performed, and evidence-based recommendations were extrapolated from the included papers. These were evaluated by a panel of 16 international experts via online surveys and subsequent consensus meeting, using nominal group technique. Recommendations were accepted when ⩾80% of experts agreed. RESULTS: In total, 7 recommendations for diagnosis and 19 for treatment of paediatric IgAV were accepted. Diagnostic recommendations included: appropriate use of skin and renal biopsy, renal work-up and imaging. Treatment recommendations included: the importance of appropriate analgesia and angiotensin-converting enzyme inhibitor use and non-renal indications for CS use, as well as a structured approach to treating IgAV nephritis, including appropriate use of CS and second-line agents in mild, moderate and severe disease along with use of angiotensin-converting enzyme inhibitors and maintenance therapy. CONCLUSION: The SHARE initiative provides international, evidence-based recommendations for the diagnosis and treatment of IgAV that will facilitate improvement and uniformity of care.
引用
- Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford). 2019. PMID: 30879080. doi:10.1093/rheumatology/kez041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。